STOCK TITAN
  1. Home
  2. Sec-filings
  3. LUNG
  4. [Form 4] Pulmonx Corp Insider Trading Activity

Pulmonx (LUNG) CCO sells shares to cover RSU tax obligations

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Pulmonx Corp’s Chief Commercial Officer Geoffrey Beran Rose reported multiple small sales of Pulmonx common stock. In total, he sold 8,023 shares at $1.54 per share on June 1, 2026.

According to the footnotes, each sale was made solely to cover tax withholding obligations tied to vesting Restricted Stock Units granted in 2023, 2024, 2025, and 2026. After these transactions, he continues to hold 463,956 Pulmonx shares directly, indicating these are routine tax-related dispositions rather than a broad reduction of his position.

Positive

  • None.

Negative

  • None.
Insider Rose Geoffrey Beran
Role CHIEF COMMERCIAL OFFICER
Sold 8,023 shs ($12K)
Type Security Shares Price Value
Sale Common Stock 1,778 $1.54 $3K
Sale Common Stock 1,557 $1.54 $2K
Sale Common Stock 2,434 $1.54 $4K
Sale Common Stock 2,254 $1.54 $3K
Holdings After Transaction: Common Stock — 463,956 shares (Direct, null)
Footnotes (1)
  1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 2, 2026.
Shares sold 8,023 shares Total Pulmonx common shares sold on June 1, 2026
Sale price $1.54 per share Price for each Pulmonx share sold on June 1, 2026
Shares held after transactions 463,956 shares Direct Pulmonx common stock holdings after reported sales
Number of transactions 4 sales Separate Pulmonx common stock sale entries on June 1, 2026
Restricted Stock Units financial
"in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs"
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rose Geoffrey Beran
(Last)(First)(Middle)
C/O PULMONX CORPORATION
700 CHESAPEAKE DRIVE
(Street)
REDWOOD CITY CALIFORNIA 94063
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Pulmonx Corp [ LUNG ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF COMMERCIAL OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/01/2026S(1)1,778D$1.54463,956D
Common Stock06/01/2026S(2)1,557D$1.54462,399D
Common Stock06/01/2026S(3)2,434D$1.54459,965D
Common Stock06/01/2026S(4)2,254D$1.54457,711D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023.
2. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.
3. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025.
4. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 2, 2026.
/s/ David Aaron Lehman, Attorney-in-Fact06/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Pulmonx (LUNG) report for Geoffrey Beran Rose?

Pulmonx reported that Chief Commercial Officer Geoffrey Beran Rose sold 8,023 shares of common stock at $1.54 per share. The transactions occurred on June 1, 2026, and are disclosed on a Form 4 insider trading report filed with regulators.

Why did Pulmonx CCO Geoffrey Beran Rose sell 8,023 LUNG shares?

The 8,023 Pulmonx shares were sold to cover tax withholding obligations related to vesting Restricted Stock Units. Footnotes state the shares correspond to RSU grants from March 2023, March 2024, March 2025, and March 2026, making them routine tax-related sales.

At what price were Geoffrey Beran Rose’s Pulmonx (LUNG) shares sold?

All reported Pulmonx sales by Geoffrey Beran Rose were executed at $1.54 per share. Four separate transactions on June 1, 2026 totaled 8,023 shares, each coded as an open-market sale and tied to RSU vesting tax obligations.

How many Pulmonx shares does the CCO hold after these reported sales?

Following the reported tax-related sales, Geoffrey Beran Rose holds 463,956 Pulmonx common shares directly. This remaining stake is substantially larger than the 8,023 shares sold, suggesting the transactions represent a small portion of his overall equity position in the company.

Are Geoffrey Beran Rose’s Pulmonx share sales a routine tax event?

Yes. Footnotes clarify the Pulmonx share sales were executed to cover tax withholding from vesting RSUs granted in 2023, 2024, 2025, and 2026. Such transactions are typically mechanical and compensation-related rather than discretionary portfolio moves reflecting a view on the stock.